Welcome to our dedicated page for NextTrip news (Ticker: NTRP), a resource for investors and traders seeking the latest updates and insights on NextTrip stock.
NextTrip, Inc. (NASDAQ: NTRP) is a technology-forward travel and media company that regularly issues news about its integrated content-to-commerce strategy. The company’s announcements highlight how it combines immersive travel media, a proprietary NXT2.0 booking engine, and brands such as Five Star Alliance, TA Pipeline, JOURNY, and Travel Magazine to connect inspiration with travel bookings.
On this page, readers can find coverage of NextTrip’s financial results, including quarterly updates that discuss revenue growth and the impact of acquisitions and platform integration. The company’s news also addresses capital-raising activities, such as private placements and preferred stock offerings, which are detailed in press releases and related SEC filings.
Because media is central to its model, a significant portion of NextTrip’s news flow focuses on JOURNY and other media properties. Articles describe the launch of JOURNY’s VOD platform, expansion across Apple TV, Roku, iOS, and Android, new app releases, and the rollout of JOURNY Originals like the TIDE food and travel series. Updates also cover distribution partnerships, including agreements aimed at expanding JOURNY’s reach in regions such as Southeast Asia.
In addition, NextTrip issues news about acquisitions and strategic initiatives, for example the completion of the TA Pipeline acquisition and the signing of a letter of intent to acquire the GoUSA TV platform and content library. These items provide insight into how the company is building its travel and media ecosystem. Investors and followers of NTRP can use this news feed to monitor developments in the company’s travel technology, media expansion, group travel platform, and financing activities.
Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first synthetic Bryostatin batch, obtained through an exclusive licensing agreement with Stanford University. This development marks a significant milestone, allowing the company to expand its research initiatives, particularly for an orally deliverable compound. The increased supply will facilitate new clinical trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's. Synaptogenix's existing studies include Bryostatin-1, which has a notable safety profile from prior cancer research.
Neurotrope and Metuchen Pharmaceuticals have completed their merger, creating a new public holding company, Petros Pharmaceuticals, trading under the symbol PTPI. Neurotrope shareholders will own approximately 49% and Metuchen shareholders 51% of Petros. This merger includes a spin-off of Neurotrope's existing assets and liabilities. Petros aims to enhance the commercialization of its lead product, Stendra®, an FDA-approved erectile dysfunction treatment, while exploring its potential shift to over-the-counter status. The merger intends to create long-term value for stakeholders.
Neurotrope, Inc. (NASDAQ: NTRP) announced its Board of Directors approved the spin-off of its subsidiary, Neurotrope Bioscience, Inc. (NBI). Shareholders of record on November 30, 2020, will receive one share of NBI for every five shares of Neurotrope held on December 7, 2020. This follows a planned merger with Metuchen Pharmaceuticals, forming a new company named Petros Pharmaceuticals, Inc. The distribution is taxable and subject to specific conditions, including shareholder approval of the merger set for November 25, 2020.
Neurotrope (Nasdaq: NTRP) has initiated a long-term Phase 2 clinical study of Bryostatin-1 for Alzheimer's disease, dosing its first patient. Supported by a $2.7 million NIH grant, this study aims to enroll about 100 patients over six months, evaluating cognitive benefits in the absence of Namenda. Previous pilot trials indicated Bryostatin-1 was well tolerated and showed promising cognitive improvements. The trial represents a key milestone for Neurotrope as it seeks to advance treatment options for Alzheimer's while planning a merger with Metuchen Pharmaceuticals.
Neurotrope has amended its merger agreement with Metuchen Pharmaceuticals, increasing Neurotrope stockholders' ownership in the new company, Petros Pharmaceuticals, to 49%. Originally, it was set at 22.5%. The merger will spin out Neurotrope's lead asset, Bryostatin-1, into a separate entity while Petros focuses on its core products: Stendra® and H-100, a treatment for Peyronie's disease. Petros aims to enhance Stendra's market presence and explore converting it to over-the-counter availability. The transaction is expected to close in the fourth quarter of 2020.
Neurotrope, Inc. (Nasdaq: NTRP) has secured a services agreement with Worldwide Clinical Trials to boost site recruitment for its Phase 2 clinical study of bryostatin-1 aimed at treating moderately severe Alzheimer's disease. Funded by a $2.7 million NIH grant, the study plans to enroll approximately 100 patients over a 6-month period, focusing on cognitive benefits using the Severe Impairment Battery score. The company anticipates dosing the first patient by late Q3 or early Q4 2020, following promising results from prior studies.